Product Details
Source
Biotinylated Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) (NUN-S47L8) was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant SARS-CoV-2 Nucleocapsid protein. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Clone
AS47
Species
Mouse
Isotype
Mouse IgG1 | Kappa
Conjugate
Biotin
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Nucleocapsid protein.
Application
ApplicationRecommended UsageELISA0.1-6.25 ng/mlPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Biotinylated Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA

Detection SARS-CoV-2 Nucleocapsid Protein by Sandwich ELISA Assay.
Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS46) (Cat. No. NUN-S46) at 4 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5227). And then add Biotinylated Anti-SARS-CoV-2 Nucleocapsid Antibody, Mouse IgG1 (AS47) (Cat. No. NUN-S47L8) at 0.05 µg/mL. Detection was performed using high sensitivity HRP-conjugated streptavidin with sensitivity of 12.5 pg/mL (QC tested).Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Nucleocapsid proteins
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
1 Details
- Highest Development Stage:
Phase 1 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















